Why Viridian Therapeutics, Inc.’s (VRDN) Stock Is Up 9.11%
As of Wednesday, November 04, Viridian Therapeutics, Inc.’s VRDN share price has surged by 9.11%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Tudor Pop
Michael Rose
Michael Rose
Cynthia McLaughlin
| Share Statistics | VRDN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,505.5 | $211.8 | 62% |
|
| Shares Out (Mil) | 113.4 | 55.4 | 64% |
|
| Institutional Ownership | 99.9% | 93.0% | 96% |
|
| Float (Mil) | 101.1 | 41.5 | 60% |
|
| Beta | 1.07 | 0.99 | 64% |
|
| Avg Daily Volume (000s) | 3,918 | 553 | 88% |
|
| Price Change (52-week) |
6.7% | 42.8% | 57% |
|
| Growth | VRDN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 130.0% | 13.2% | 99% |
|
| Net Income (5yr) | (25.4%) | (10.3%) | 16% |
|
| EPS (5yr) | 36.1% | 15.8% | 86 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (25.8%) | (15.7%) | 25% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 13 | 13 | |
| Current EPS | ($0.738) | ($3.505) | ($2.131) | |
| Month Ago EPS | ($0.948) | ($3.884) | ($2.740) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | ($0.997) | ($3.949) | ($2.773) | |
| Year/Year Chg | (8.4%) | 5.4% | (96.1%) | |
| Financials | VRDN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $26 | $41 | 15% |
|
| Net Income (TTM) (Mil) | ($454) | ($44) | 3% |
|
| EPS (TTM) | ($3.804) | ($1.500) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($342) | ($35) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $-0 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $245 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $2,630 | $147 | 53% |
|
| Valuation | VRDN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.26 | 2.01 | 88% |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VRDN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (56.5%) | (47.4%) | 10% |
|
| ROE | (113.9%) | (53.1%) | 8% |
|
| Liabilities to Assets | 43.5% | 29.7% | 35% |
|
| F-Score | 2 | 3 | 7% |
|
Viridian Therapeutics, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors